2Westin J,RoDjer S,Turesson I,et al. Interferon alfa- zb versus no maintenance therapy during the plateu phase in multiple myelomo:a randomized study. Br J Haematol 1995;89:561
3Montuoro A, Resa LD, Blasio AD, et al. Alpha - 2a - interferon/melphalan/predrisone versus melphalan/prednisone in perviously untreated patients with multiple myelome. Br J Hacmatol 1990;76:365
5[3]Singhal S,Mehta J,Desikan R,et al.Antltumor activity of thalidomide in refractory multiple myoloma[J].N Engl J Med,1999,341(18):1565-1571.
6[5]Haslett PA,Corral LG,Albert M,et al.Thalidomide costimulates primary human Tlymphocytes preferentially inducing proliferation,cytokine production,and cytotoxic responses in the CDB+subset[J].J Exp Mep,1998,187(11):1885-1892.
7[8]Kneller A,Raanani P,Hardan I,et al.Therapy with thalidomide in refractory Multiple myeloma patients-the revival of an old drug[J].Br J Nematol,2000,108(2):391.
8Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT.European Group for Blood and Marrow Transolant[J].Br J Haematol.1998.10(2):1115-1123.
9Sung B,Kunnumakkara AB,Sethi G,et al.Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model [J].Mol Cancer Ther,2009,8(4):959-970.
10Hatcher H,Planalp R,Cho J,et al.Curcumin: from ancient medicine to current clinical trials [J].Cell Mol Life Sci,2008,65(11):1631-16 52.
